Neuropathic pain affects millions of people worldwide, causing substantial disability and greatly impairing quality of life. Commonly used analgesics or antihyperalgesic compounds are generally characterized by limited therapeutic outcomes. Thus, there is a compelling need for novel therapeutic strategies able to prevent nervous tissue alterations responsible for chronic pain. The a9a10 nicotinic acetylcholine receptor antagonist a-conotoxin RgIA (RgIA), a peptide isolated from the venom of a carnivorous cone snail, induces relief in both acute and chronic pain models. To evaluate potential disease-modifying effects of RgIA, the compound was given to rats following chronic constriction injury (CCI) of the sciatic nerve. Two or 10 nmol RgIA injected intramuscularly once a day for 14 days reduced the painful response to suprathreshold stimulation, increased pain threshold to nonnoxious stimuli, and normalized alterations in hind limb weight bearing. Histological analysis of the sciatic nerve revealed that RgIA prevented CCI-induced decreases of axonal compactness and diameter, loss of myelin sheath, and decreases in the fiber number. Moreover, RgIA significantly reduced edema and inflammatory infiltrate, including a decrease of CD86 + macrophages. In L4-L5 dorsal root ganglia, RgIA prevented morphometric changes and reduced the inflammatory infiltrate consistent with a disease-modifying effect. In the dorsal horn of the spinal cord, RgIA prevented CCI-induced activation of microglia and astrocytes. These data suggest that RgIA-like compounds may represent a novel class of therapeutics for neuropathic pain that protects peripheral nervous tissues as well as prevents central maladaptive plasticity by inhibiting glial cell activation. Ó
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Introduction
Damage to the somatosensory nervous system may result in the induction of neuropathic pain [8] . Metabolic or infective diseases, antiviral or anticancer chemotherapies, multiple sclerosis, and trauma each may give rise to nervous system alterations that induce painful sensory neuropathies [4] . A pathological plasticity of nervous system circuitries causes the development of a chronic pain syndrome and results in reduced efficacy of classical analgesic drugs prescribed to treat neuropathic pain [53] . The widely used opioids, for example, are less effective in neuropathic pain because the mechanisms that contribute to chronic neuropathic pain may simultaneously contribute to diminishing the antinociceptive properties of opioids [12] . Most of the clinically available neuropathic pain treatments were originally developed for other therapeutic indications such as epilepsy or depression, or for local anesthesia. Recent additions to the pharmacopeia include ziconotide (an N-type calcium channel antagonist obtained from a cone snail) and tapentadol (an opioid agonist and norepinephrine reuptake inhibitor) [2] . These medications provide partial symptomatic 
